What does the fracturing of vaccine advice and policy mean for the U.S. health care ecosystem? Will the potential head of the Centers for Disease Control ...

Viking Therapeutics VKTX announced that it has initiated the phase III VANQUISH program, evaluating the subcutaneous (SC) ...

Drugs such as Ozempic (a brand name for semaglutide) are showing promise for weight loss. Another medication in the same ...

Amgen’s first quarter results reflected robust demand across its portfolio, with product volumes and sales increasing in both ...

Alternatives to weekly injections of weight-loss drugs may be on the way. A monthly dose of a new drug called MariTide helped ...

The once-monthly drug is still under study but could provide added convenience and another option for patients.

A new drug from California-based pharma company Amgen, which has concluded a phase II trial, shows promise as a powerful ...

Eli Lilly, Novo Nordisk and Amgen release weight loss drug data as competition heats up in the market, while Abridge ...

If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...

An experimental obesity drug has shown it can “substantially” reduce weight within a year, offering new hope for people with ...

Thousand Oaks, California Wednesday, June 25, 2025, 13:00 Hrs [IST] ...

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.